Integrative Use of Ningmitai Capsule and Cefoxitin in Treating Post‐Ureteroscopic Lithotripsy Stent‐Related Urinary Tract Infections
Year: 2026
Type: article
Abstract: Ureteral stent placement following ureteroscopic lithotripsy (URL) reduces obstruction but increases the risk of urinary tract infection (UTI). Conventional antibiotic therapy alone is often insufficient. Ningmitai capsule, a traditional Chinese herbal preparation, has demonstrated anti-inflammatory and antibacterial activity. This study evaluated the efficacy, safety, and translational value of combining Ningmitai with cefoxitin. A retrospective controlled study included 76 patients who developed UTI after URL with stent placement between May 2023 and October 2024. Patients were stratification-matched to a cefoxitin-only group (n = 38, cefoxitin only) or a combined group (n = 38, cefoxitin plus Ningmitai). Clinical efficacy, urinary symptom scores, inflammatory markers [high-sensitivity C-reactive protein (hs-CRP), interleukin-1β (IL-1β), procalcitonin (PCT)], and adverse reactions were compared. Logistic regression identified independent predictors, and decision curve analysis (DCA) assessed clinical net benefit. The combined group achieved a higher efficacy rate than the cefoxitin-only group (94.74% vs. 78.95%, p = 0.042). Dysuria, urinary frequency, hematuria, and renal colic improved more significantly, and hs-CRP, IL-1β, and PCT levels decreased to a greater extent in the combined group (all p < 0.001). Combination therapy was an independent predictor of success (OR = 4.52, 95% CI: 1.56-13.06). The predictive model improved AUC from 0.71 to 0.91. DCA showed superior net benefit between 0.1-0.5 thresholds. Adverse events were rare and comparable between groups. Ningmitai capsule combined with cefoxitin improves symptoms, reduces inflammation, and maintains safety in stent-associated UTI after URL. Predictive modeling and DCA confirm its translational potential as an integrative therapeutic approach.
DOI: 10.1111/cts.70553
Authors: Gang Chen, Jun Zhou
Institution: Suzhou Traditional Chinese Medicine Hospital
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,630
OpenAlex ID: W7160708877
